We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


NIH Issues $2.87 Million Drug Development Grant to Cerageneix

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NIH Issues $2.87 Million Drug Development Grant to Cerageneix"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Ceragenix Pharmaceuticals, Inc. has announced that the National Institutes of Health (NIH) has awarded a $2.87 million grant to fund the pre clinical development of a Ceragenin™ based oral drug to treat two common and potentially deadly gastrointestinal infections: Clostrdium difficile and Shigella. The grant will fund the preclinical development, formulation, toxicology and cGMP scale up to 1 kilogram of CSA-13.

The research grant has been awarded to a consortium of research institutions led by Brigham Young University (BYU) and including SRI International (Menlo Park, CA), Southwest Research Institute (SwRI, San Antonio, TX) and McMaster University (Hamilton, Ontario, Canada). Ceragenins™ are a class of novel antimicrobial compounds that mimic functions of the body’s own innate immune system.

The Ceragenin™ technology was invented by Dr. Paul B. Savage (Reed Izatt Professor at BYU) and has been exclusively licensed by BYU to Ceragenix. There have been over 30 peer reviewed scientific publications on this novel class of compounds.